Takano K, Iino K, Ibayashi S, Tagawa K, Sadoshima S, Fujishima M
Cerebrovascular Center, National Fukuoka-Higashi Hospital, Japan.
Am J Cardiol. 1994 Nov 1;74(9):935-9. doi: 10.1016/0002-9149(94)90590-8.
The hemostatic condition under low-intensity anticoagulation in cardiac disorders is not fully elucidated. The aim of this study was to ascertain whether hemostatic molecular markers are a useful assessment for anticoagulation to detect the hypercoagulable state. A hematologic study was performed in 75 outpatients, without thromboembolic episodes, treated with low-intensity anticoagulation (average international normalized ratio [INR] 1.72) because of potential cardiac sources of arterial emboli, and in 40 age-matched control subjects. The average level of thrombin-antithrombin III complex (TAT) was significantly lower in patients than in control subjects (p = 0.005), and the mean value of D-dimer was not statistically different between patients and control subjects. Although TAT correlated moderately with D-dimer (r = 0.45, p = 0.0001), INR did not correlate with TAT or D-dimer. Elevated TAT > 3.0 ng/ml and/or D-dimer S 150 ng/ml were observed in 15 patients (20.0%), whereas the remaining 60 patients (80.0%) had no obvious increase in the level of TAT or D-dimer at overall INR. Antithrombin III activity did not correlate significantly with INR, but protein C activity and free protein S antigen showed a significant negative relation to INR (r = 0.82, r = 0.62, respectively, p = 0.0001). Low-intensity anticoagulation was sufficient to reduce coagulation and subsequent fibrinolytic activation in cardiac disorders, but may not be sufficient in some patients with elevated TAT or D-dimer concentration.(ABSTRACT TRUNCATED AT 250 WORDS)
心脏疾病中低强度抗凝治疗下的止血状态尚未完全阐明。本研究的目的是确定止血分子标志物是否是评估抗凝治疗以检测高凝状态的有用指标。对75例因潜在心脏动脉栓塞源而接受低强度抗凝治疗(平均国际标准化比值[INR]为1.72)且无血栓栓塞事件的门诊患者以及40例年龄匹配的对照受试者进行了血液学研究。患者的凝血酶 - 抗凝血酶III复合物(TAT)平均水平显著低于对照受试者(p = 0.005),患者与对照受试者之间D - 二聚体的平均值无统计学差异。尽管TAT与D - 二聚体呈中度相关(r = 0.45,p = 0.0001),但INR与TAT或D - 二聚体无相关性。15例患者(20.0%)观察到TAT>3.0 ng/ml和/或D - 二聚体S 150 ng/ml升高,而其余60例患者(80.0%)在总体INR水平下TAT或D - 二聚体水平无明显升高。抗凝血酶III活性与INR无显著相关性,但蛋白C活性和游离蛋白S抗原与INR呈显著负相关(分别为r = 0.82,r = 0.62,p = 0.0001)。低强度抗凝足以降低心脏疾病中的凝血及随后的纤溶激活,但对一些TAT或D - 二聚体浓度升高的患者可能不足够。(摘要截短至250字)